TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29205690

Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (ICM) for 20 months monitoring
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Software based analysis of continuously monitored electrocardiogram (SRA) during hospitalization
Number of subjects: 105

Group type: COMPARATOR
Intervention: SRA compared to ICM
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ICM detection of AF
Number of subjects: 105

Group type: COMPARATOR
Intervention: SRA prediction of AF
Number of subjects: 105
Study: 29206049

Group type: EXPERIMENTAL
Intervention: Biodegradable wafers impregnated with carmustine (BCNU)
Number of subjects: 500
Study: 29206476

Group type: EXPERIMENTAL
Intervention: Coulter blood counts and proportions
Number of subjects: 6299
Study: 29206771

Group type: EXPERIMENTAL
Intervention: Any VMS
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Mild VMS
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Moderate VMS
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Severe VMS
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Duration of VMS
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Night sweats only
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Night sweats and hot flashes
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Hot flashes only
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Late VMS
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Early and late VMS
Number of subjects: 150007

Group type: EXPERIMENTAL
Intervention: Early VMS
Number of subjects: 150007
Study: 29206944

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (9.6 nmol/kg, one injection)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (9.6 nmol/kg, two injections at 10 h interval)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Kisspeptin-54
Number of subjects: 48

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 48

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 48
Study: 29207608

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) dose adjustment following therapeutic drug monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotype-guided BU dose adjustments
Number of subjects: 0
Study: 29207962

Group type: EXPERIMENTAL
Intervention: 12-month exercise program including ≥2.5 hours of intense physical activity/week, 30 minutes of strength building, and 2 hours of aerobic exercises.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group asked to keep physical activity levels constant.
Number of subjects: 150
Study: 29207966

Group type: EXPERIMENTAL
Intervention: HPV-based cervical cancer screening in community health campaigns
Number of subjects: 18

Group type: COMPARATOR
Intervention: HPV-based cervical cancer screening in health facilities
Number of subjects: 18
Study: 29207976

Group type: EXPERIMENTAL
Intervention: Body image discrepancy assessment among girls who chose a smaller ideal body figure than their current/actual figure (67.5%; n=1023)
Number of subjects: 1519

Group type: EXPERIMENTAL
Intervention: Weight status assessment
Number of subjects: 1519
Study: 29207983

Group type: EXPERIMENTAL
Intervention: CHW-led health coaching with EHR-based interventions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EHR-based interventions (hypertension-specific registry reports, alerts, and order sets)
Number of subjects: 16
Study: 29208007

Group type: EXPERIMENTAL
Intervention: One session of physical therapy
Number of subjects: 14
Study: 29208025

Group type: EXPERIMENTAL
Intervention: Cardiac index variation during the Trendelenburg maneuver
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cardiac index variation during end-expiratory occlusion test
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pulse pressure variation during tidal volume challenge
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Change in pulse pressure variation during tidal volume challenge
Number of subjects: 33
Study: 29209023

Group type: EXPERIMENTAL
Intervention: BCI system with online scaling feature
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard BCI control without online scaling feature
Number of subjects: 2
Study: 29209104

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: IL-6R antagonist therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Baseline CD4CD69 ratio < 2.43
Number of subjects: 92
Study: 29209458

Group type: EXPERIMENTAL
Intervention: Pre-meal almond group (PM) - 56 g of almonds consumed before meals
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Snack almond group (SN) - 56 g of almonds consumed as a snack between meals
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (CL) - high-carbohydrate iso-caloric control food
Number of subjects: 169
Study: 29209510

Group type: EXPERIMENTAL
Intervention: Milrinone infusion
Number of subjects: 66
Study: 29209513

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sidestream darkfield microscopy (SDF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging (LSCI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bolus of ephedrine
Number of subjects: 40
Study: 29209515

Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium chain triglyceride ketogenic diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both ketogenic diets
Number of subjects: 12
Study: 29209525

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily; 3 week continuous treatment cycles)
Number of subjects: 1066
Study: 29209636

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFNB-1a)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Serum NF-L
Number of subjects: 85
Study: 29209946

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks via pen
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks via pen
Number of subjects: 217

Group type: COMPARATOR
Intervention: Sarilumab 150 mg every 2 weeks via syringe
Number of subjects: 217

Group type: COMPARATOR
Intervention: Sarilumab 200 mg every 2 weeks via syringe
Number of subjects: 217

Group type: COMPARATOR
Intervention: Sarilumab pen and syringe groups
Number of subjects: 217
Study: 29210056

Group type: EXPERIMENTAL
Intervention: Blood-based precision medicine test (ASGES)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: High ASGES group
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low ASGES group
Number of subjects: 176
Study: 29210351

Group type: EXPERIMENTAL
Intervention: Malaria treatment during pregnancy, specific intervention details not provided.
Number of subjects: 0
Study: 29210443

Group type: EXPERIMENTAL
Intervention: ACC-001 3 µg + QS-21 adjuvant (50 µg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ACC-001 10 µg + QS-21 adjuvant (50 µg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ACC-001 + QS-21
Number of subjects: 63
Study: 29210791

Group type: EXPERIMENTAL
Intervention: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase I
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase II
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Closed-loop control of remifentanil in phase II
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Closed-loop control of remifentanil in phase I
Number of subjects: 127
Study: 29211516

Group type: EXPERIMENTAL
Intervention: Racial discrimination
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Low household education
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Racial discrimination (girls only)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Low household education (girls only)
Number of subjects: 198
Study: 29211618

Group type: EXPERIMENTAL
Intervention: Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy
Number of subjects: 535

Group type: COMPARATOR
Intervention: Combined positive lymph node status and LOH 1p or 16q
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Delayed nephrectomy (histology results)
Number of subjects: 535
Study: 29211620

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 4252

Group type: COMPARATOR
Intervention: quadrivalent HPV vaccine (qHPV)
Number of subjects: 4252
Study: 29211678

Group type: EXPERIMENTAL
Intervention: Gene therapy with AAV vector (5×10 dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Before vector administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: After vector administration
Number of subjects: 10
Study: 29211870

Group type: EXPERIMENTAL
Intervention: Denosumab (fixed-dose, cumulative dose 47 to 98 mg/kg for 1.3 to 4 years)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Denosumab (fixed-dose)
Number of subjects: 3
Study: 29212126

Group type: EXPERIMENTAL
Intervention: extended-duration betrixaban (35–42 days)
Number of subjects: 7513

Group type: COMPARATOR
Intervention: enoxaparin (10 ± 4 days)
Number of subjects: 7513

Group type: EXPERIMENTAL
Intervention: D-dimer ≥ 2×ULN
Number of subjects: 7513

Group type: EXPERIMENTAL
Intervention: D-dimer at baseline
Number of subjects: 7513
Study: 29212518

Group type: EXPERIMENTAL
Intervention: High HDL-C levels
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Low HDL-C levels
Number of subjects: 775

Group type: COMPARATOR
Intervention: HDL-C category or continuous HDL-C levels
Number of subjects: 775
Study: 29212544

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 61
Study: 29212734

Group type: EXPERIMENTAL
Intervention: Neoadjuvant GTX (gemcitabine 750 mg/m², docetaxel, capecitabine)
Number of subjects: 40
Study: 29213110

Group type: EXPERIMENTAL
Intervention: 7.5% CO for 8 minutes
Number of subjects: 0
Study: 29213213

Group type: EXPERIMENTAL
Intervention: Course in group leadership
Number of subjects: 56
Study: 29213243

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) efficacy on CHF patients
Number of subjects: 110
Study: 29213269

Group type: EXPERIMENTAL
Intervention: ME-TRAP and EPI vaccines
Number of subjects: 65

Group type: COMPARATOR
Intervention: EPI vaccines only
Number of subjects: 65
Study: 29213281

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside (mean dose 1100 mg, with some patients receiving above 1000 mg)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Number of subjects: 282
Study: 29214012

Group type: EXPERIMENTAL
Intervention: 2 years of perennial AIT using PURETHAL Mites
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 29214034

Group type: EXPERIMENTAL
Intervention: Abatacept (~10 mg/kg/month)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 29214042

Group type: EXPERIMENTAL
Intervention: Lifestyle enhanced Parents as Teachers curriculum (PATE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parents as Teachers curriculum (PAT)
Number of subjects: 0
Study: 29214306

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 2348

Group type: EXPERIMENTAL
Intervention: Both RYGB and LAGB
Number of subjects: 2348
Study: 29214505

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-based cryogenic device (EndWarts Freeze)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dimethylether propane-based product (Wartner)
Number of subjects: 0
Study: 29214922

Group type: EXPERIMENTAL
Intervention: HAES®-based intervention (exercise program, nutrition counseling sessions, philosophical workshops)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional HAES®-based group format (bimonthly lectures)
Number of subjects: 60
Study: 29216318

Group type: EXPERIMENTAL
Intervention: Day-by-day approach
Number of subjects: 676

Group type: COMPARATOR
Intervention: Week-by-week approach
Number of subjects: 676
Study: 29216353

Group type: EXPERIMENTAL
Intervention: Hormonal therapy in transwomen
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hormonal therapy in transmen
Number of subjects: 69
Study: 29216356

Group type: EXPERIMENTAL
Intervention: Combined isolation of exosomal RNA (exoRNA) and cell-free DNA (cfDNA) (exoNA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Circulating tumor DNA (ctDNA) by BEAMing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combined isolation of exosomal RNA (exoRNA) and cell-free DNA (cfDNA) (exoNA) in M0/M1a subgroup (n=21)
Number of subjects: 84
Study: 29216358

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 6583

Group type: COMPARATOR
Intervention: Control (no BCG)
Number of subjects: 6583
Study: 29216400

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg bd
Number of subjects: 53
Study: 29216439

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 80
Study: 29216838

Group type: EXPERIMENTAL
Intervention: Routine mobilisation and targeted hospital interventions for patients identified with reduced physical performance.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Simplified prediction model based on 4 variables: use of a walking aid before hospitalisation, a 30s-CST score ≤ 5, age > 85, and female gender.
Number of subjects: 117
Study: 29216886

Group type: EXPERIMENTAL
Intervention: Integration of PCIT into existing practices
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quality monitoring
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Financing
Number of subjects: 12
Study: 29216999

Group type: EXPERIMENTAL
Intervention: Coronary bioresorbable scaffolds (BRS)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Optimal implantation technique
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Reference vessel diameter (RVD) and BRS sizing
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Incomplete BRS deployment
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Large vessel size and BRS undersizing
Number of subjects: 657
Study: 29217099

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) scores during pregnancy
Number of subjects: 1078
Study: 29217288

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed disease progression, unacceptable toxicity, or other criterion for withdrawal.
Number of subjects: 249
Study: 29217502

Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Intervention (coaching software on mobile phone)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 163
Study: 29217776

Group type: EXPERIMENTAL
Intervention: Melphalan 200 mg/m
Number of subjects: 0
Study: 29217778

Group type: EXPERIMENTAL
Intervention: Constitutional mutations (p.H880Q, p.R986H, p.R986C, p.V1512M) identified through genomic studies
Number of subjects: 7
Study: 29218759

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) using EQ-5D-5L
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory v2 Short Form
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: SF-36v2 health survey
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Hemophilia Activities List
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Hemophilia Joint Health Score v2.1 (HJHS)
Number of subjects: 381
Study: 29219612

Group type: EXPERIMENTAL
Intervention: Avelumab treatment
Number of subjects: 88
Study: 29220505

Group type: EXPERIMENTAL
Intervention: ab+/ins- (antibody positive/insulin negative)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: ab+/ins+ (antibody positive/insulin positive)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: ab-/ins- (antibody negative/insulin negative)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Controls (glucose-tolerant humans)
Number of subjects: 41
Study: 29220868

Group type: EXPERIMENTAL
Intervention: Diabetic cohort (DM)
Number of subjects: 4839770

Group type: COMPARATOR
Intervention: Nondiabetic cohort (non-DM)
Number of subjects: 4839770
Study: 29221433

Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 29221483

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 34
Study: 29221494

Group type: EXPERIMENTAL
Intervention: Pap-smears performed by GPs
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Male GPs performing pap-smears
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Female GPs performing pap-smears
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Screening rates in target population when GPs performed smears
Number of subjects: 347

Group type: COMPARATOR
Intervention: Screening rates in target population when GPs did not perform smears
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Use of claim code by GPs
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Association of number of patients and EDI with pap-smears
Number of subjects: 347
Study: 29221777

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 246

Group type: COMPARATOR
Intervention: Nonthrombolysis
Number of subjects: 246
Study: 29222077

Group type: EXPERIMENTAL
Intervention: Dynamic Facebook content (1 to 2 status updates per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Static Facebook content (96 statuses viewed on the first day)
Number of subjects: 21
Study: 29222080

Group type: EXPERIMENTAL
Intervention: 12-item self-report WHODAS 2.0 administered online
Number of subjects: 160
Study: 29222121

Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 87
Study: 29222199

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at initial doses of 1.8 or 2.4 mg/kg every 3 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 7
Study: 29222649

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (two 220 mg capsules of zinc sulfate per day for 3 months)
Number of subjects: 60
Study: 29223443

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d) for 18 months
Number of subjects: 101
Study: 29223478

Group type: EXPERIMENTAL
Intervention: Veliparib 300 mg twice-daily (N = 3) then 400 mg twice-daily (N = 15) days 1-28
Number of subjects: 16
Study: 29223912

Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine dose at delivery
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Maternal buprenorphine dose
Number of subjects: 41

Group type: COMPARATOR
Intervention: NNNS domain scores
Number of subjects: 41
Study: 29224196

Group type: EXPERIMENTAL
Intervention: Posterior cervical angle (PCA) > 99.5°
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cervical length < 34 mm
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bishop score > 5
Number of subjects: 70
Study: 29224239

Group type: EXPERIMENTAL
Intervention: Stepwise vascular occlusion technique
Number of subjects: 80
Study: 29224367

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (starting dose of 15 or 20 mg BID, final titrated dose of ≥10 mg BID)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (higher doses of 20 or 25 mg BID)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 81
Study: 29224506

Group type: EXPERIMENTAL
Intervention: High-dose AAV5-hFVIII-SQ
Number of subjects: 9
Study: 29224973

Group type: EXPERIMENTAL
Intervention: Residual pulmonary embolism with percentage of vascular obstruction 0.1%-4.9%
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Residual pulmonary embolism with percentage of vascular obstruction 5.0%-9.9%
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Residual pulmonary embolism with percentage of vascular obstruction greater than or equal to 10%
Number of subjects: 239

Group type: COMPARATOR
Intervention: No residual pulmonary embolism on baseline ventilation-perfusion scan
Number of subjects: 239
Study: 29225195

Group type: EXPERIMENTAL
Intervention: First 1000Days program
Number of subjects: 3
Study: 29225893

Group type: EXPERIMENTAL
Intervention: Partial Jejunal Diversion (PJD)
Number of subjects: 15
Study: 29225899

Group type: EXPERIMENTAL
Intervention: Intervention group parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29225903

Group type: EXPERIMENTAL
Intervention: Prasugrel or ticagrelor as loading P2Y inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin with optional glycoprotein IIb/IIIa inhibitor treatment
Number of subjects: 0
Study: 29225901

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 14
Study: 29226174

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 218

Group type: COMPARATOR
Intervention: Matched non-HIV-infected subjects
Number of subjects: 218
Study: 29226268

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Latanoprost (one drop daily at bedtime for seven days)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Timolol, atropine, and prednisolone
Number of subjects: 1
Study: 29226764

Group type: EXPERIMENTAL
Intervention: CTL019 cells (CD19-directed CAR T cells)
Number of subjects: 28
Study: 29226797

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) CAR T-cell therapy
Number of subjects: 111
Study: 29228942

Group type: COMPARATOR
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in healthy controls
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in patients with sarcoidosis
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in patients with bronchial asthma
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Duplicate measurements of Lung Clearance Index (LCI) in patients with COPD
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Test time reduction in COPD
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Within-test repeatability of LCI
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Mean absolute changes in LCI
Number of subjects: 153